Bio Platforms

EXECUTIVE INTERVIEW – Enteris BioPharma: Pioneers in Oral Formulation Development

Dr. Rajiv Khosla, CEO of Enteris BioPharma, discusses how his company’s innovative oral formulation technology is helping the pharmaceutical industry overcome the hurdle of low bioavailability to reshape treatment categories and expand market opportunities with minimal financial and regulatory risks.

THERAPEUTIC PEPTIDES – Continuous Manufacturing of Peptides Could Speed Up Development, Reduce Costs & Improve Quality

Jens Bukrinski, PhD, MSc, says the high-quality, high-process consistency between manufacturing runs and the in-line PAT analytics of the μLOT platform will enable unprecedented robustness of the manufacturing process, significantly retiring the risk of failure to supply due to non-scalability of the manufacturing process.

EXCLUSIVE ONLINE CONTENT